In the meta-analysis of the pooled data set, BRAF mutations remained more frequent in NMZL (9%, 4/43) reaching statistical significance against SMZL (1%, 2/215, p ≤ 0.01, Fisher’s exact test). The gene discussed is BRAF; the disease is nodal marginal zone B-cell lymphoma.